Personalized Cancer Treatment Market Report 2026

The personalized cancer treatment market size has grown rapidly in recent years. It will grow from $200.98 billion in 2025 to $222.54 billion in 2026 at a compound annual growth rate (CAGR) of 10.7%. The growth in the historic period can be attributed to limited access to genetic testing, reliance on conventional chemotherapy, low awareness of personalized medicine benefits, fragmented oncology healthcare infrastructure, lack of targeted therapy approvals.

The personalized cancer treatment market size is expected to see rapid growth in the next few years. It will grow to $332.37 billion in 2030 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to growing investment in genomics research, increasing adoption of liquid biopsy and biomarker testing, rising demand for targeted therapies and immunotherapies, integration of ai and big data in treatment planning, expansion of precision oncology clinical trials. Major trends in the forecast period include increasing adoption of ai-based genomic analytics for cancer treatment, rising implementation of precision medicine platforms, growing use of biomarker-based diagnostic techniques, increasing integration of digital health solutions in oncology, rising adoption of immersive technologies for patient monitoring and education.

The rising prevalence of cancer is expected to drive the growth of the personalized cancer treatment market in the coming years. The increase in cancer cases is largely associated with longer life expectancy, resulting in more individuals reaching ages at which cancer is more common, as well as greater exposure to risk factors such as tobacco use, alcohol consumption, and obesity. Personalized cancer treatments offer targeted and effective therapeutic approaches to address various cancer types and stages, and the expanding disease burden is encouraging investment and innovation in precision medicine to improve patient outcomes through customized treatment strategies. For instance, in February 2024, according to the World Health Organization, a Switzerland-based United Nations agency focused on global health, the global cancer burden is projected to increase substantially, with new cancer cases expected to rise by 77% to more than 35 million by 2050, compared to 20 million cases in 2022. Therefore, the increasing prevalence of cancer is driving the growth of the personalized cancer treatment market.

Major companies operating in the personalized cancer treatment market are emphasizing the development of advanced solutions, such as artificial intelligence-enabled multimodal immune profile algorithmic tests, to better predict patient responses to immunotherapy and strengthen personalized treatment approaches. An AI-enabled multimodal immune profile algorithmic test evaluates multiple data types, including genomic, transcriptomic, and clinical biomarkers, to determine a patient’s immune profile and forecast their potential response to immunotherapy, supporting patient stratification and treatment decision-making. For example, in July 2024, Tempus AI, Inc., a US-based health technology company, launched its AI-enabled multimodal immune profile algorithmic test (IPS), representing its first entry into the immunotherapy diagnostics segment. This research-use-only test analyzes immunotherapy-related biomarkers to generate a predictive score that supports personalized cancer treatment by improving patient selection and treatment planning.

In December 2023, Pfizer Inc., a US-based pharmaceutical and biotechnology company, acquired Seagen Inc. for $43 billion. Through this acquisition, Pfizer seeks to strengthen its oncology portfolio by leveraging Seagen’s advanced antibody-drug conjugate technology to expand the development of targeted cancer therapies. This strategic transaction is intended to accelerate Pfizer’s growth in the oncology sector and address the increasing demand for more effective cancer treatments. Seagen Inc. is a US-based biotechnology company specializing in monoclonal antibody-based therapies for cancer treatment.

Major companies operating in the personalized cancer treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche, Merck & Co. Inc., Bristol Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca Plc, Novartis AG, BioNTech SE, Illumina Inc., Artera, Exact Sciences Corporation., Moffitt Cancer Center, Myriad Genetics, NeoGenomics Laboratories, Guardant Health, Caris Life Sciences, Tempus AI Inc., Foundation Medicine, Immatics, Fate Therapeutics, CureVac AG, TScan Therapeutics, CureMetrix, PDC*line Pharma.

North America was the largest region in the personalized cancer treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized cancer treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the personalized cancer treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the personalized cancer treatment market by raising costs for imported genomic sequencing tools, diagnostic kits, and therapeutic components, affecting hospitals, clinics, and research institutes primarily in North America and Europe. While tariffs have increased operational costs and slowed some market expansion, they have also encouraged domestic manufacturing, local innovation in precision oncology solutions, and the development of cost-efficient diagnostics and therapies, providing long-term strategic benefits.

The personalized cancer treatment market research report is one of a series of new reports that provides personalized cancer treatment market statistics, including personalized cancer treatment industry global market size, regional shares, competitors with a personalized cancer treatment market share, detailed personalized cancer treatment market segments, market trends and opportunities, and any further data you may need to thrive in the personalized cancer treatment industry. This personalized cancer treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Personalized cancer treatment involves tailoring therapies according to an individual’s specific genetic makeup and tumor characteristics to deliver more precise and effective interventions. This approach improves treatment strategies and patient outcomes by analyzing genetic mutations and biomarkers, offering advantages over conventional one-size-fits-all treatment methods.

The primary types of personalized cancer treatment include targeted therapy, immunotherapy, hormone therapy, chemotherapy, radiation therapy, and others. Targeted therapy employs drugs or other agents that selectively identify and attack cancer cells while minimizing damage to healthy cells. Diagnostic methods such as genomic sequencing, liquid biopsy, immunohistochemistry, in situ hybridization, biomarker testing, and other techniques are applied across cancer types including breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, and others, and are utilized by end users such as hospitals and clinics, research institutes, and others.

The personalized cancer treatment market consists of revenues earned by entities by providing services such as genetic testing, biomarker analysis, personalized therapy formulation, and targeted drug delivery. The market value includes the value of related goods sold by the service provider or included within the service offering. The personalized cancer treatment market also includes sales of products including targeted therapy drugs, genomic profiling kits, and companion diagnostics. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.